Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2011. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) regarding their personal holdings of the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is the share price of £12.23 per Ordinary share, which was the price used for the re-investment of dividends paid on April 7, 2011.
Material Changes
The filing details an increase in share interests for specific directors and connected persons following the re-investment of dividends. There are no reported material changes to the company's financial position or operations in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is strictly a regulatory disclosure of insider share transactions.
Important Facts for Investors
- Transaction Type: Increase in shareholdings via dividend re-investment.
- Share Price: £12.23 per Ordinary share.
- Key Participants: Mr. A P Witty (999 shares), Mrs. C M Witty (894 shares), Dr. D Pulman (420 shares), Mrs. C R Pulman (85 shares), and Mr. I W Whyte (69 shares).
- Notification Date: April 11, 2011.
- Regulatory Basis: Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).